102 Conversely, a number of teams are advocating for the incorporation of novel markers, such as a elaborate karyotype55 or epigenetic subsets, 27,28 into clinical follow. Each one of these novel prognostic and/or predictive products will have to be validated in cohorts of patients dealt with with targeted brokers.Klik tombol daftar di situs Intern